Multi-Center PAMPA Study
NCT05004727
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Psoriasis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- NYU Langone Health
- Last updated on ClinicalTrials.gov
- March 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
New York · 2
- NYU Langone Health · New York, NY
- University of Rochester Medical Center (URMC) · Rochester, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.